Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.090 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cassava Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
WHY: NEW YORK, NY - (NewMediaWire) - February 06, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of... 
Via NewMediaWire
Topics Lawsuit
ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
WHY: NEW YORK, NY - (NewMediaWire) - February 06, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of... 
Via TheNewswire.com
Topics Lawsuit
News headline image
3 small-cap biotechs with potential breakthroughs in 2024
These small-cap biotech stocks feature large addressable markets combined with positive analyst sentiment and potential breakthroughs in 2024. 
Via MarketBeat
Topics Bankruptcy
News headline image
Cassava ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Cassava Sciences Inc. (NASDAQ: SAVA) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
High short interest stocks: this popular trend is re-emerging
Renewed optimism has led to higher risk tolerance in stocks, which has brought back a popular trend: Stocks with high short interest are gaining popularity 
Via MarketBeat
Topics ETFs
News headline image
Cassava Sciences Appoints Three New Members to its Board of Directors
Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. Government 
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
CEO to Present on Wednesday, October 11th, at 10:30am ET 
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
New Research Shows Simufilam Suppresses Overactive mTOR
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
New Publication Highlights Basic Science Supporting Simufilam
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences to Present at the Jefferies Global Healthcare Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.